The BCL2 Knockout Ca Ski Polyclonal Cells are a CRISPR/Cas9-edited polyclonal cell population derived from the Ca Ski cervical carcinoma line, featuring targeted disruption of the BCL2 gene to eliminate expression of the anti-apoptotic BCL2 protein. This genetically heterogeneous pool captures diverse CRISPR/Cas9 editing outcomes, providing a versatile loss-of-function model without requiring clonal isolation. By abrogating BCL2??s protective function, these cells serve as a reliable platform for apoptosis, drug resistance, and cancer cell survival studies in an HPV16-positive background.
The Ca Ski parental line is a well-established model of cervical squamous cell carcinoma, originally from an epidermoid carcinoma metastasis. These adherent epithelial cells are HPV16-positive and retain integrated viral genomes, exhibiting constitutive activation of PI3K/AKT and NF-??B pathways partly driven by HPV oncoproteins E6 and E7. This background provides a relevant context for examining the interplay between viral oncogenesis and the intrinsic apoptotic machinery.
BCL2 localizes to the mitochondrial outer membrane, where it inhibits MOMP by sequestering BAX and BAK. Its expression is upregulated by NF-??B, STAT3, and CREB via PI3K/AKT and JAK/STAT signaling, and is responsive to IL-3 and EGF. Pro-apoptotic BH3-only proteins such as BAD, BIM, and PUMA neutralize BCL2, while BID and NOXA directly activate BAX/BAK. Upon BCL2 loss, BAX/BAK oligomerize, triggering cytochrome c release, APAF1 apoptosome formation, and activation of caspase-9 and caspase-3. BCL2 also interacts with BECN1 to regulate autophagy, further influencing cell survival.
In Ca Ski cells, BCL2 knockout removes a key anti-apoptotic block, sensitizing these HPV16-positive cells to intrinsic apoptotic signals. This line depends on BCL2, BCL2L1, and MCL1 to evade death and resist agents like cisplatin. Disabling BCL2 may reveal dependence on other survival pathways, aiding identification of synthetic lethal interactions and testing BH3 mimetics. Thus, this model is valuable for studying apoptosis in HPV-driven cervical cancer and exploring chemoresistance mechanisms.
Applications include apoptosis assays such as Annexin V/PI staining, caspase activity measurements, cytochrome c release analyses, and JC-1 mitochondrial membrane potential assays. The knockout cells are suitable for BCL2 inhibitor screening, drug sensitivity testing, and validation of BCL2 interaction partners like BAX, BAK, and caspase-9 via western blotting. They also facilitate investigation of HPV-related oncogenic signaling. For further information, contact Ascent Research.
